ClinicalTrials.gg
Not yet recruitingNCT05784350Updated Oct 9, 2026

Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesia-Induced Hypotension

An interventional study of fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone in Intra-operative Hypotension, sponsored by Meir Medical Center. Not yet recruiting at 1 site in Israel. Open to participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Meir Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hypotension with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Hypotension · Israel.

Planned enrollment
3rd of 11
150 · median 100
Started
2027
the only one that year
No phase
6 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
2 of 12
Meir Medical Center

Among the 12 studies in Hypotension with a site in Israel, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2027, is one of 6 with no phase, and was the 12th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

1 of the 12 studies in Hypotension with a site in Israel is open now.

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 19 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypotension with a site in Israel, or all of them as a file.
02

Study summary

Hypotension is a common side-effect of general anesthesia induction and is related to adverse outcomes including significantly increasing risk of one-year mortality. Even short durations of intraoperative hypotension have been associated with acute kidney injury (AKI) and myocardial injury.Half of all the patients were fluid-responsive, pointing to volume status as a significant risk factor. Ultrasound measurements of inferior vena cava (IVC) diameter with respiration, including the maximal diameter of the IVC (dIVCmax) at the end of expiration during spontaneous respiration and the collapsibility index (CI), have been recommended as rapid and noninvasive methods for estimating volume status.

In attempt to prevent hypotension after spinal anesthesia induction, Ondansetron, a serotonin receptor antagonist, has been used effectively .

Research Question Can preoperative IVC-US guided fluid optimization and intravenous ondansetron reduce the incidence of general anesthesia-induced hypotension in adult patients undergoing elective non-cardiac non-obstetric surgery?

03

Conditions studied

  • Intra-operative Hypotension

Browse trials for

04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18
  2. Elective, non-cardiac, non-obstetric surgery under general anesthesia
  3. physical status classification I - III

Exclusion criteria

Exclusion Criteria:

  1. MAP below 60 mmhg prior to the induction of general anesthesia.
  2. Patients treated with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) on the day of surgery.
  3. Patients with heart failure with (EF) \< 40%.
  4. Patients with documented acute or chronic renal failure.
  5. Patients with hepatic failure.
  6. Patients with neuraxial (spinal/epidural) anesthesia performed before induction of general anesthesia.
  7. Patients with suspected difficult airway.
  8. Patients with documented allergy to Ondansetron or prolonged -syndrome.

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Intravenous fluid bolus

    Drug: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone

  • Active comparator
    Intravenous Ondansetron

    Drug: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone

  • No intervention
    No intervention

Interventions

  • Drugfluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone

    group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L. Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.

06

What researchers measure

Primary outcomes

  1. Efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia

    To determine the efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia in adults presenting for elective non-cardiac, non-obstetric surgery.

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for May 2028, 15 months later.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Feb 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartEst.
Feb 1, 2027was Aug 2025
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2025→Feb 1, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Aug 1, 2025→Feb 1, 2027
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05784350
Responsible party
sara dichtwald (Dr, Meir Medical Center) — Principal investigator
First posted
Mar 24, 2023
Start date
Feb 1, 2027 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Sara Dichtwald, Dr
Contact
sara.dichtwald@clalit.org.il
972-9-7472133 ext. 1

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion